company background image
LLY logo

Eli Lilly DB:LLY Stock Report

Last Price

€718.50

Market Cap

€644.7b

7D

1.6%

1Y

130.3%

Updated

27 Mar, 2024

Data

Company Financials +

LLY Stock Overview

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.

LLY fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance1/6
Financial Health1/6
Dividends0/6

Eli Lilly and Company Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Eli Lilly
Historical stock prices
Current Share PriceUS$718.50
52 Week HighUS$737.00
52 Week LowUS$309.90
Beta0.34
1 Month Change1.20%
3 Month Change36.60%
1 Year Change130.25%
3 Year Change355.38%
5 Year Change519.02%
Change since IPO1,164.10%

Recent News & Updates

Recent updates

Shareholder Returns

LLYDE PharmaceuticalsDE Market
7D1.6%2.3%1.9%
1Y130.3%-25.9%7.3%

Return vs Industry: LLY exceeded the German Pharmaceuticals industry which returned -25.9% over the past year.

Return vs Market: LLY exceeded the German Market which returned 7.3% over the past year.

Price Volatility

Is LLY's price volatile compared to industry and market?
LLY volatility
LLY Average Weekly Movement4.1%
Pharmaceuticals Industry Average Movement6.3%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: LLY's share price has been volatile over the past 3 months.

Volatility Over Time: LLY's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
187643,000Dave Rickshttps://www.lilly.com

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.

Eli Lilly and Company Fundamentals Summary

How do Eli Lilly's earnings and revenue compare to its market cap?
LLY fundamental statistics
Market cap€644.75b
Earnings (TTM)€4.84b
Revenue (TTM)€31.52b

133.8x

P/E Ratio

20.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LLY income statement (TTM)
RevenueUS$34.12b
Cost of RevenueUS$7.08b
Gross ProfitUS$27.04b
Other ExpensesUS$21.80b
EarningsUS$5.24b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Apr 30, 2024

Earnings per share (EPS)5.82
Gross Margin79.25%
Net Profit Margin15.36%
Debt/Equity Ratio233.4%

How did LLY perform over the long term?

See historical performance and comparison

Dividends

0.7%

Current Dividend Yield

78%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.